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2Abstract
Background. Symptomatic oesophageal cancer is usually advanced and 
terminates fatally. There is a need for biomarkers to help pathologists 
recognise patients at increased risk of squamous and glandular 
oesophageal cancers (in the case of Barrett's oesophagus). The work 
described in this thesis looks at four topics: cytokeratin 7 and 20 
phenotypes in Barrett's intestinal metaplasia; the distribution of 
cardiac, cardio-oxyntic and 'specialised' intestinal-type Barrett's 
mucosa in relation to glandular dysplasia; dysregulated expression of the 
proliferation marker Ki67 and the DNA replication-licensing proteins Mcm2 
and Mcm5 in glandular and squamous dysplasia; and relates different types 
of complete (type I) and incomplete (types IIA/IIB) intestinal metaplasia 
to dysplasia/neoplasia in Barrett's oesophagus.
Results. Cytokeratin 7 and 20 phenotypes are complex and variable, 
so likely clinical utility is not immediately obvious. The ubiquitous 
presence of intestinal metaplasia (IM) in Barrett's mucosa is confirmed, 
and a very strong association of IM with dysplasia. A positive 
association exists between dysplasia and type IIB intestinal metaplasia, 
and an even stronger negative association with type I intestinal 
metaplasia. This identifies a possibility that robust markers of 
(complete) small intestinal metaplasia may be associated with low 
dysplasia risk in Barrett's oesophagus, whereas a potentially colonic 
phenotype (type IIB IM) is associated with greater risk.
Over-expression of the cel1-proliferation related antigen Ki67 and 
the DNA replication licensing proteins Mcm2 and Mcm5 in the 
differentiated surface compartment of squamous oesophageal epithelium and 
Barrett's mucosa confirm the Mem proteins are promising markers of 
oesophageal dysplasia meriting further evaluation, e.g. in the field of 
non-endoscopic oesophageal cytology.
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Chapter 1: General Introduction
The Clinical Challenge of Oesophageal Cancer
Squamous carcinoma and adenocarcinoma of the oesophagus together 
rank amongst the top ten cancers in the world, and oesophageal 
adenocarcinoma was increasing more rapidly than any other cancer in the 
United States and Europe during the 1990s [1,2].
Two distinct types of dysplasia are associated with oesophageal 
cancer: glandular dysplasia in Barrett's oesophagus is considered 
precancerous for adenocarcinoma, and squamous dysplasia for squamous cell 
carcinoma (SCC). Barrett's adenocarcinoma is frequent in the United 
States and other western countries, whereas squamous cancer is 
particularly common in Asia, including China and Japan.
Mortality for oesophageal cancer is close to its incidence, as most 
patients present late with symptoms of advanced disease, when treatment 
is relatively ineffective [2]. In Barrett's oesophagus, progression may 
be detected in patients attending an endoscopic surveillance program, 
which is a recommended clinical management strategy for this disease. 
However, despite a better prognosis for surveillance detected cancer [3]/ 
there is debate whether the low absolute risk of oesophageal cancer in 
Barrett's oesophagus justifies the expense of surveillance endoscopy and 
biopsy. While studies of the incidence of oesophageal cancer suggest a 
three- to five-fold increase over the last 30-40 years, the overall 
number of individuals with oesophageal adenocarcinoma remains relatively 
low [4,5]. It has been calculated that even if there was a treatment 
that halved the risk of progression to carcinoma in Barrett's oesophagus, 
400 patients would have to be treated to prevent one case of cancer pen 
annum [6].
Better understanding of molecular events leading to carcinoma of 
the oesophagus may, ultimately, allow treatment to be focused towards 
minimising disease progression in those most at risk. This applies 
equally to patients in the West, with Barrett's oesophagus and elevated 
adenocarcinoma risk, and Asian populations susceptible to squamous 
cancer.
Oesophageal Squamous Cancer
Squamous epithelial dysplasia is thought to be the precancerous 
lesion in SCC: approximately 70% of patients with squamous dysplasia 
eventually develop SCC with a 5 year survival rate of 5-35% [7], Up to 
the 1990s, when it was overtaken by adenocarcinoma, squamous cell 
carcinoma was the predominant form of oesophageal cancer in the United 
States. However SCC of the oesophagus remains one of the most common 
cancers in China with -250,000 cases diagnosed every year [8].
Epidemiological studies have identified tobacco smoking [9], 
alcohol drinking, dietary habits and environmental agents, such as 
nitrosamines, as major risk factors in squamous cell carcinomas of the 
oesophagus [8,10].
The incidence of oesophageal SCC varies markedly throughout China 
but even in high-risk areas only a small proportion of people develop it, 
suggesting possible host susceptibility factors [8]. Genetic 
polymorphisms in carcinogen-metabolizing enzymes may modify individual 
susceptibility to cancer. Tan et al [8] demonstrated a significant 
association between oesophageal SCC and genetic polymorphisms of CYP2E1, 
an enzyme responsible for the metabolic activation of many carcinogens 
including nitrosamines, which is expressed at significant levels in human 
oesophagus. Such genetic markers could prove useful in targeting 
resources at groups most at risk of disease progression.
9Oesophageal Adenocarcinoma
In western countries, especially the US and UK, the frequency of 
adenocarcinoma of the oesophagus has increased substantially over several 
decades [11]. Adenocarcinomas of the oesophagus mainly develop from 
Barrett's oesophagus (figure 1), a condition in which a variable length 
of the non-keratinising stratified squamous epithelium, which lines the 
normal oesophagus, is replaced by an acid-resistant columnar, glandular 
mucosa.
Figure 1/1: endoscopic and histological appearance of normal and 
Barrett's oesophagus. A: Normal endoscopy looking towards OG junction.
B: Red velvety Barrett's mucosa contrasts with pale squamous mucosa. C: 
Oesophageal stratified squamous epithelium. D: Barrett's mucosa. The 
goblet cells are characteristic of intestinal metaplasia.
Glandular metaplasia is thought to follow chronic gastro- 
oesophageal reflux, and patients with Barrett's oesophagus have up to a 
100 fold higher risk of developing adenocarcinoma of the oesophagus than
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the general population [12]. Unfortunately, most Barrett's cancers are 
incurable at diagnosis, with overall 5 year survival only 7% [13].
Diagnosis of Barrett's Oesophagus
It is estimated 30% of adults in western countries complain of 
heartburn at least once a month, a third of whom will have endoscopic 
evidence of oesophagitis. 40% of patients with oesophagitis will improve 
spontaneously, but 50% will have persistent oesophagitis and 10% will 
progress to Barrett's metaplasia [14]. Barrett's oesophagus is much more 
common among men than women and is present in approximately 10% of all 
patients undergoing routine GI upper endoscopy with chronic 
gastroesophageal reflux symptoms, but how well this reflects the 
prevalence of the condition in the general population is not known 
[13,14]. The prevalence of Barrett's oesophagus in the population is 
also uncertain, as many people with Barrett's oesophagus do not have 
reflux symptoms, perhaps due to the greater resistance of the columnar- 
lined oesophagus to acid reflux. Lastly, many patients have symptoms 
which are not investigated, so there is potentially a large number of 
undiagnosed cases. Based on an autopsy series, Cameron et al [15] 
estimated that for every known patient with Barrett's oesophagus there 
might be 20 unrecognised cases in the general population.
Three mucosal patterns have been described in the columnar lined 
oesophagus. These resemble either gastric or intestinal mucosa [16,17];
a) Gastric cardiac (so-called junctional type) mucosa resembles 
normal cardiac epithelium and has typical mucus secreting cells lining 
the surface pits and simple mucus-secreting glands.
b) Gastric fundic type mucosa is characterised by mucus cells on the 
surface with chief and parietal cells in the deeper parts of the glands.
c) Intestinal type mucosa has a villous surface lined by columnar 
and goblet cells. Deep in the mucosa are clear mucus secreting glands
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with enterochromaffin cells and sometimes Paneth cells. This is often 
called 'specialised' mucosa.
No correlation has been found between the type of mucosa in 
Barrett's oesophagus and the degree of inflammation, ulceration, 
stricture formation or length of columnar segment. In most cases there 
is a mixture of phenotypes with specialised intestinal-type mucosa the 
most common [16-19]. Classically, a diagnosis of Barrett's oesophagus is 
established when columnar epithelium extends for several cm above the 
oesophago-gastric junction (OGJ) [20,21], An alternative classification 
does not rely on endoscopic measurements, which may be imprecise, but on 
the presence of a columnar-lined oesophagus regardless of length so long 
as it is associated with 'specialised' intestinal metaplasia [20].
!
I Long segment Barrett's oesophagus is defined as the abnormal
presence of specialised intestinal metaplasia in a segment of columnar 
epithelium extending 3cm or more into the oesophagus from the OGJ. Short
| segment Barrett's oesophagus is defined as the presence of specialised
!
| intestinal metaplasia in a segment less than 3cm above the OGJ [21].
i
|
j The prevalence of short segment Barrett's oesophagus has been
|
reported at 8-32% in routine upper gastrointestinal endoscopy. There is 
the same white male predominance in both short and long segment Barrett's 
oesophagus, although the male predominance may be less in short segment 
Barrett's oesphagus. The length and duration of upright and supine acid 
exposure are greater in long segment Barrett's oesophagus and there is a 
greater lower oesophageal sphincter incompetence and impairment of 
oesophageal peristalsis [21] . Reflux symptoms are reported by 58-82% of 
short segment Barrett's oesophagus patients and 60% of long segment 
Barrett's oesophagus patients [22].
Early adaptive responses to increased cell loss in reflux 
oesophagitis is trophic stimulation by locally produced growth factors 
leading to an increased thickness of the proliferative zone and increased 
proliferative zone length with folding of the basal epithelium and
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papilla formation. The functional stem cells at the tip of the papillae 
remain in a relatively superficial position leaving them exposed to 
reflux.
Intestinalization of the cardiac mucosa occurs when cardiac-like 
columnar cells develop acid rather than neutral mucins and goblet cells 
appear, but the specific cellular events that induce the change from 
cardiac mucosa to specialised intestinal mucosa are unknown.
De Meester and De Meester [23] suggested that patients with >3cm of 
intestinalized Barrett's mucosa had, on average, a longer duration of 
reflux symptoms {10 v. 5 years) and a greater exposure to refluxed 
bilirubin than patients with «3cm of Barrett's oesophagus without 
intestinal metaplasia. Barrett's oesophagus in children differs from the 
adult variety in that intestinal mucins and cytokeratins are not present, 
and typically adults show an inflammatory cell infiltrate which is less 
common in juvenile Barrett's metaplasia.
Barrett's oesophagus has been described following caustic burns and 
chemotherapy, but it is accepted that the replacement of oesophageal 
squamous epithelium by columnar mucosa is usually acquired secondary to 
gastro-oesophageal reflux [14].
When a patient is found to have Barrett's oesophagus, the length of 
time it has been present is usually unknown. Cameron et al [24]
estimated the mean age of development of Barrett's to be 40 years with a
mean age of diagnosis 63 years.
Pathogenesis of Barrett's oesophagus
Intraoesophageal pH recordings have established that patients with
Barrett's oesophagus have more acid reflux events and longer acid
clearance times compared to oesophagitis patients without columnar mucosa 
[25]. Patients with Barrett's oesophagus frequently have impaired 
oesophageal motility with low contraction amplitudes and an increased 
frequency of abnormal waveforms in the distal oesophagus compared with
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normal subjects [23]. Bremner [26] argued that the columnar-lined 
oesophagus was a protective response to acid reflux and thought it 
unlikely that further acid reflux would be involved in the pathogenesis 
of Barrett's complications. Barrett's oesophagus has developed after 
total gastrectomy, so acid reflux is not the sole factor responsible for 
this disease [27]. Elevated intragastric bile acid concentrations in 
patients with complications of Barrett's oesophagus such as strictures, 
ulcers, or adenocarcinomas may indicate that these patients have a 
diffuse motor abnormality of the upper gastrointestinal tract involving 
the lower oesophageal sphincter and the pylorus [25]. Lagergren et al 
[28] found that lower oesophageal sphincter relaxing medications were 
associated with increased risk for oesophageal adenocarcinoma, probably 
through promotion of reflux.
Structurally defective lower oesophageal sphincters have been 
demonstrated in more than 90% of those with Barrett's oesophagus.
Patients who reflux both gastric and duodenal juice have been shown to 
have a higher prevalence of oesophagitis than those who only reflux 
gastric juice. Additionally, among patients with Barrett's oesophagus, 
significantly greater oesophageal bilirubin exposure (a marker of 
duodenal reflux) has been demonstrated in those in whom dysplasia 
develops [23].
Evidence is accumulating that bile salts are a toxic component in 
refluxed duodenal juice and their ability to cause cellular injury is pH 
dependent. For bile salts to enter mucosal cells and cause injury they 
must be soluble and un-ionized. At pH 7 > 90% of bile salts are in 
solution and completely ionized. Acidification of bile to a pH of < 2 
produces irreversible precipitation so, under normal physiologic gastric 
conditions, bile acids precipitate and are of minimal significance. 
However, in a less acid gastric environment, as can occur with 
pharmacological acid suppression, bile salts are partially dissociated at 
pH 3-5 and a mixture of ionized salts and un-ionized salts are present. 
Un-ionized bile salts can rapidly cross mucosal cell membranes. Once
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inside the alkaline environment of the cell they are converted back to 
their ionized form, so become trapped within the cell, accumulate and 
become toxic to the mitochondria.
For bile acids to remain completely ionized and innocuous in a 
patient with reflux disease, a pH of 7 would have to be maintained 24 
hours a day. One study demonstrated that normal volunteers taking 20mg 
of Omeprazole twice a day spend more than 30% of a 24 hour period with a 
gastric pH of less than 4, therefore insufficient doses of medication may 
allow oesophageal mucosal cell injury to occur while the patient remains 
relatively asymptomatic [29].
The hydrogen-ion ('proton') pump inhibitor (PPI) Omeprazole is 
largely metabolised by cytochrome P450 isozyme CYP2C19. This isozyme is 
absent in about 3% of Caucasians and 12-20% of orientals. Poor 
metabolizers, heterozygous extensive metabolizers and homozygous 
extensive metabolizers represent 3%, 30% and 67% of Caucasians. Poor 
metabolizers are exposed to Omeprazole to a larger extent than extensive 
metabolizers and as Omeprazole is widely used to inhibit gastric acid 
secretion in the treatment of gastro-oesophageal reflux disease, the 
individual's capacity to metabolize the drug will influence its efficacy 
[30]. As many patients with Barrett's oesophagus have few or no reflux 
symptoms, probably as a consequence of an altered sensitivity of the 
metaplastic epithelium to the refluxed acid, their symptoms are an 
unreliable guide to treatment and eradication of heartburn does not 
ensure elimination of acid reflux. Increasing the dose of Omperazole 
until symptoms were alleviated was shown to be an unreliable measure of 
effective therapy by Katza et al as 80% of these patients were found to 
have abnormal oesophageal acid exposure on 24-hour pH monitoring [31].
The main aim of therapy for Barrett's oesophagus is to control 
symptoms. Patients must continue medication indefinitely, usually by 
proton pump inhibition, but even high dose therapy may not prevent 
nocturnal acid regurgitation and the advent of increasingly potent 
inhibitors of acid production over the last 20 years has not prevented
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the rising incidence of oesophageal adenocarcinoma [28,32]. There is no 
medical treatment as yet for alkaline reflux of bile or pancreatic juice 
and standard medical antireflux therapy does not reduce the length of the 
Barrett's segment [17]. Antireflux surgery with fundoplication can be 
performed to control acid exposure in the short term, but adenocarcinoma 
progression after fundoplication has been documented [17,33]. There is 
speculation that medical therapy of prolonged and inadequate acid 
supression may actually promote the development of Barrett's oesophagus. 
One study reported that the risk of oesophageal adenocarcinoma was three 
times higher among patients who used medication for symptoms of reflux 
compared to those who did not [34].
The presence of a gastric type mucosa within the oesophagus is a 
prerequisite for Helicobacter pylori (H. pylori) colonisation and H. 
pylori may contribute to the severity of inflammation in Barrett's 
epithelium. There is wide variation in the reported prevalence of 
H.pylori in Barrett's oesophagus. Henihan et al [35] found H. pylori in 
gastric mucosa only and more commonly associated with chronic moderate to 
severe inflammation. In the presence of H. pylori 89.5% of Barrett's 
patients had moderate to severe chronic inflammatory changes in contrast 
with 36.5% of those without.
H. pylori produces urease, vacuolase cytotoxin (vac A), cytotoxin- 
associated gene A (cag A) and phospholipidases which may directly injure 
the mucosa. H. pylori oesophageal infection is invariably associated 
with gastric colonisation. In some patients with H. pylori gastritis, 
serum gastrin is elevated with diminished somatostatin expression, which 
leads to elevated gastric acid secretion and may worsen oesophageal acid 
injury.
In Henihan's study [35] none of those with evidence of dysplasia or 
adenocarcinoma associated with Barrett's oesophagus had evidence of H. 
pylori colonisation. Henihan et al postulated that altered properties of
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the intercellular junction (the usual site for H. pylori attachment) were 
preventing H. pylori adherence.
Oxygen-derived free radicals, the superoxide anion especially are 
involved in the pathogenesis of reflux oesophagitis. Neutrophils, 
macrophages and monocytes are the main sources of this radical and anti­
inflammatory drugs may reduce acid and pepsin induced injury. A mixed 
inflammatory infiltrate is common in peptic oesophagitis, especially in 
the stem-cell rich areas of the basal mucosal compartment and papilla. 
This infiltrate is initially composed of acute inflammatory cells, 
subsequently T lymphocytes become more numerous, especially in tissues in 
which metaplastic foci develop. Even if acid reflux is suppressed, 
Barrett's metaplasia maintains a mild chronic inflammatory infiltrate 
[36] .
Genetic factors may play a role as individuals with Barrett's 
oesophagus, oesophageal adenocarcinoma or oesophagogastric junctional 
adenocarcinoma are more likely to have a positive family history of these 
diseases than individuals without Barrett's oesophagus, oesophageal 
adenocarcinoma or oesophagogastric junctional adenocarcinoma. Barrett's 
oesophagus has a familial association and may occur in twins. Many 
patients with gastro-oesophageal reflux disease (GORD) have relatives 
with reflux symptoms and several families have multiple members having 
Barrett's oesophagus and sometimes oesophageal adenocarcinoma, often 
involving more than one generation [37], Some family members had 
oesophagitis without Barrett's oesophagus, suggesting that the inherited 
factor might be a propensity to reflux. Patients with a first degree 
relative with GORD are twice as likely to have GORD themselves whereas 
those reporting a spouse with GORD are not [38]. So a positive family 
history could be of consideration when making decisions about screening 
patients with gastro-oesohageal symptoms.
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Stratifying Cancer Risk in Barrett's; Oesophagus
2-5% of patients with Barrett's oesoplhagus will eventually deve.op> 
oesophageal adenocarcinoma, which appears usually to develop through * 
metaplasia-dysplasia-adenocarcinoma sequencee [2,14]. Although different- 
studies quote varying levels of risk, there is an estimated 30-40 tiims 
greater incidence of adenocarcinoma of the (oesophagus in patients witi 
Barrett's oesophagus than in the general population [39].
In order to target resources towards .'surveillance and treatment of 
those most at risk of developing oesophageaH adenocarcinoma, it is 
necessary to utilise known risk factors asscociated with progression o: 
the disease.
It is recognised that specialised intcestinal-type Barrett's 
metaplasia measuring any length is associateed with all grades of 
dysplastic change and carries a higher risk of malignant change [40,41], 
Skinner [42] suggested and Reid [13] and th«en Haggitt [17] confirmed :hd-t 
only the intestinal type of columnar mucosa is definitely premalignam, 
although cases of adenocarcinoma associated with the pure fundic or 
junctional types of columnar metaplasia havee also been reported [43]. 
Specialized intestinal metaplasia of the oesophagus is retrospectively 
diagnosed in 79-100% of oesophageal adenocaircinomas and in 42-73% of 
adenocarcinomas at the OGJ [3].
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Figure 1/2: Adenocarcinoma arising in Barrett's oesophagus. This 
advanced lesion presented with dyspagia. The prognosis is poor. Top - 
squamous lined oesophagus. Bottom - gastric mucosa. Single arrows - 
proximal limit of Barrett's mucosa. Double arrows - oesophagogastric 
junction.
Progression to cancer in patients with Barrett's oesophagus is 
associated with loss of cell cycle regulation, accumulation of multiple 
genetic abnormalities and the appearance of multiple aneuploid cell 
populations [10,44-47]. Overexpression of p53 and increased proportions 
of cells with a G2 DNA content are observed in Barrett's oesophageal 
metaplastic epithelium, probably as a result of chronic cell and DNA 
damage induced by gastric reflux [10,45-47], Subsequent p53 mutations 
and 17p allelic losses result in the inactivation or alteration of the 
p53 gene which disrupts the Gl/S transition control and aneuploid cell 
populations develop [10].
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Neshat et al [2] found aneuploid cell populations in 86% of high 
grade and/or adenocarcinoma in Barrett's oesophagus, with different 
aneuploid populations occupying defined but sometimes overlapping spatial 
distributions. Apoptosis may also be inhibited late in a proportion of 
dysplastic cells, and over-expression of various oncogenes and growth 
factors have been reported [14]. Barrett's oesophagus patients with 
increased G2 fraction or aneuploid cell populations could be targeted for 
more frequent endoscopic surveillance. P53 mutation is not essential for 
malignant transformation in Barrett's oesophagus so p53 abnormality alone 
may not reliably predict malignant progression [44], Neither of these 
possible strategies has been validated in practice.
Recognising Dysplasia
The reported prevalence of adenocarcinoma in Barrett's oesophagus 
averages approximately 10% at the time the initial diagnosis of Barrett's 
oesophagus is made [2,17,41]. Adenocarcinoma patients usually present 
with advanced disease [33,41] and have a 5-year survival of only 5-10%, 
compared to 50% for early lymph-node negative disease and 80% for high 
grade dysplasia/carcinoma in situ or stage 1 cancer following 
oesophagectomy [33]. The prognosis of oesophageal cancer is related to 
the depth of invasion and spread to adjacent lymph nodes [48]. 
Unfortunately Barrett's adenocarcinomas are rarely discovered in time for 
cure and 93% of patients who develop adenocarcinoma will die of the 
disease [2], hence the need for surveillance to detect dysplasia at its 
earliest stage.
A sequence from mild or low grade dysplasia to severe or high grade 
dysplasia with progression to carcinoma is thought to occur, based on the 
frequent finding of high grade dysplasia in the mucosa surrounding 
adenocarcinoma, and the progression of high grade dysplasia to 
adenocarcinoma in prospective series [49] . Dysplasia is Coofi-AQ cK t"o 
(rke fcxxs b^ (r cAoes. not eWso. pe/^ . In
low grade dysplasia the nuclei are enlarged, crowded and hyperchromatic,
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but confined to the lower half of the cells. Goblet and columnar cell 
mucus are diminished. In high grade dysplasia there is distortion of the 
crypt architecture with 'back to back' glands. The abnormalities seen in 
low grade dypsplasia are more pronounced in high grade dysplasia and 
nuclear abnormalities reach the luminal surface of the cells. Epithelium 
that is atypical but not definitely dysplastic can be classified as 
'indefinite for dysplasia'.
Figure 1/3. On the left of this photomicrograph there is typical 
'intestinal type' Barrett's mucosa (A). In the middle there is an abrupt 
transition to moderate (low grade) glandular dysplasia (B). 
Characteristically dysplasia involves the mucosal surface.
Figure 1/4. A: High grade Barrett's dysplasia (severe dysplasia
/adenocarcinoma in situ). B : intramucosal Barrett's
adenocarcinoma.
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The ability to detect curable neoplastic disease in patients with 
Barrett's oesophagus is a prerequisite for prospective endoscopic 
surveillance. Once invasive adenocarcinoma develops it may intially be 
difficult to detect as is reliable endoscopic differentiation between HGD 
alone and HGD with early foci of adenocarcinoma. Dysplasia may occur in 
the absence of any endoscopic lesion and may be hidden underneath 
regenerated squamous epithelium [32,50].
Four quadrant biopsies at iMc/uals or less throughout the
length of the Barrett's oesophageal segment plus biopsies of any lesions 
are usually recommended to minimise sampling error [17]. The intensity 
of surveillance varies from a 3 yearly interval for those in whom 
dysplasia has never been seen to 6-12 monthly in low grade dysplastic 
cases [32] . The treatment of those with high grade dysplasia is 
controversial, some advocate oesophagectomy [50], others close endoscopic 
surveillance every 3-6 months [13,51],
The ability to distinguish high grade dysplasia and early 
adenocarcinoma from lesser histological abnormalities is acceptable but 
imperfect (average interobserver agreement of 85-87%)[17]. The ability 
to differentiate intramucosal adenocarcinoma from high grade dysplasia 
may require examination of numerous tissue sections to detect early 
invasion. Also, the diagnosis of invasive adenocarcinoma arising from 
the bases of dysplastic glands may be compromised because endoscopic 
samples may be inadequate. Significant interobserver and intraobserver 
variation exists in grading dysplasia at the indefinite/low grade 
interface [17].
A confirmed endoscopic biopsy diagnosis of early Barrett's 
adenocarcinoma often leads to surgery, but the diagnosis of high grade 
dysplasia poses the question of whether surgery should follow.
The risk of progression from high grade dysplasia to cancer is high 
[17,32,33], with adenocarcinoma that was unidentified preoperatively in 
approximately 40% of oesophagectomy cases [32,33,50]. These patients are
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likely to have resectable disease and have an improved five years 
survival compared with patients with symptomatic cancer detected outside 
a surveillance program [32] . On the other hand, some high grade 
dysplastic cases have regressed, 27% in one study to lesser grades of 
dysplasia and even to non-dysplastic mucosa [32] . Operative mortality of
3-6% and significant morbidity as high as 40% [32,52] are an obvious 
consideration especially since high grade dysplasia can sometimes be
j eradicated by endoscopic treatments including photodynamic therapy [52],
|
i which involves light-induced activation of an administered
I
| photosensitiser in tissue to produce local necrosis. However, only
! tumours at an early stage allow a good response to photodynamic therapy,
| so such treatment appears to have its greatest potential benefit in
treating patients with HGD and early Barrett's adenocarcinoma, especially 
| those who are high risk candidates for operation. Another ablation
therapy is multipolar electrocautery using a probe that transmits 
electrical energy to the epithelium to cause a superficial injury, 
although in some cases ablation therapy has led to re-epithelialization 
over intestinal metaplasia which may still harbour a neoplastic risk 
[33,52]. Endoscopic mucosal resection is another minimally invasive 
therapeutic strategy which also does not carry the risk of major surgery.
Young fit patients with HGD in Barrett's oesophagus should still be 
offered operation for fear of missing early cancer. In patients at risk, 
surgery may be reserved until endoscopic surveillance detects evidence of 
invasion. So there is ongoing debate about the clinical management of 
patients in whom endoscopic biopsy samples show only high grade dysplasia 
and any methods that could assist identification of cancer development 
and reduce diagnostic error in patients with Barrett's oesophagus would 
prove very useful.
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The need for improved surveillance
The cost of endoscopic surveillance is considerable and its value 
has been questioned [53], which has led to studies evaluating non- 
endoscopic surveillance techniques for Barrett's patients using balloon 
cytology [34] and nasogastric brush cytology [54].
Mass screening with balloon cytology is well described in China for
| the detection of oesophageal squamous cell carcinoma and dysplasia [55].
[
\ Falk et al [34] found balloon cytology detected 80% of patients with high
i
grade Barrett's dysplasia and/or adenocarcinoma when sampling was 
adequate. The potential cost savings of these techniques supports 
| further studies into their potential in the surveillance and follow up of
I Barrett's oesophageal patients. Theoretically, sampling errors could be
| reduced by assessing brushings taken from the whole of the Barrett's
epithelium, as foci of dysplasia or cancer can seem macroscopically 
normal so could be missed by endoscopy and biopsy.
Some patients whose biopsies show histologically abnormal tissue 
will progress to cancer whereas others will remain stable or even
i
regress. A better understanding of the early events in neoplastic 
progression in Barrett's oesophagus might indicate those patients a risk 
of subsequent progression to adenocarcinoma. More than three million 
people in the United States have Barrett's oesophagus. There is a clear 
need to stratify the risk for progression to adenocarcinoma in these 
patients. To date the most predictive factor is degree of dyplasia. New 
methods of detecting dysplasia and more specific markers for neoplasia 
should improve the reliability of surveillance.
The work described in this thesis addresses four areas of interest 
in Barrett's oesophagus. These are: a, the possible existence of 
characteristic cytokeratin 7 and 20 phenotypes in Barrett's metaplasia 
(which might be useful in discriminating short and ultra-short Barrett's 
oesophagus from intestinal metaplasia related to gastric pathology in the 
proximal stomach); b, the distribution of different mucosal phenotypes
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(intestinal, cardiac, cardio-oxyntic) in long-segment Barrett's 
oesophagus, and their relationship with glandular dysplasia; c, the 
potential of the cell proliferation marker Ki67 and the DNA replication 
licensing proteins as markers of glandular and squamous oesophageal 
dysplasia; and finally, d, whether any relationship can be detected 
between different subtypes of intestinal metaplasia (type I v. type IIA 
v. type IIB) and dysplasia in Barrett's oesophagus.
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Chapter 2: Recognising Barrett’s Oesophagus 
Cytokeratin Phenotypes in Barrett's oesophagus
The metaplastic glandular cells of Barrett's mucosa have 
ultrastructural features of squamous and glandular cells, and also 
express cytokeratins (CK) of both cell origins [56]. Two distinct Ck 
7/20 expression patterns have been described in intestinal metaplasia of 
Barrett's oesophagus and intestinal metaplasia of the gastric 
cardia,(table 2/1), and this has been used to distinguish between 
intestinal metaplasia at the OGJ and SSBE [57],
Dysplasias and cancers tend to retain patterns of Ck expression 
that characterise the cells and tissues from which they originate, so 
cytokeratin phenotypes could help to demonstrate whether or not 
adenocarcinoma of the cardia and the oesophagus originate from distinct 
cell types.
The cardia, the anatomical region of transition between the 
oesophagus and stomach, cannot be identified macroscopically. It is 
visible microscopically as a thin glandular mucosa without acid-secreting 
oxyntic cells [58]. Intestinal metaplasia occurs at the cardia 
particularly with chronic inflammation but there is no clear evidence 
that this metaplasia predisposes to the development of adenocarcinoma of 
the cardia.
Biopsy specimens obtained from the OGJ may have been obtained from 
either the distal oesophagus or the gastric cardia and there is debate as 
to whether adenocarcinomas of the cardia and lower oesophagus share a 
common pathogenesis. Short segment Barrett's oesophagus is believed to be 
caused by GORD whereas intestinal metaplasia of the cardia is often 
associated with H. pylori infection, and the dysplasia risk is greater in 
short segment Barrett's oesophagus compared to cardia intestinal 
metaplasia [59].
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Intestinal metaplasia is detectable in mucosa adjacent to 89% of 
adenocarcinomas of the oesophagus, 58% of adenocarcinomas of the cardia 
and 33% of adenocarcinomas of the subcardia [60].
Cytokeratins 7 and 20 are cytoplasmic structural proteins, 
constituents of the intermediate filaments of epithelial cells, and their 
expression patterns help to assign likely origins to many epithelial 
tumours including those of the gastrointestinal tract. A Ck 7 +/20- 
immunophenotype is present in 90% of Barrett's adenocarcinomas but only 
21% of gastric adenocarcinomas[61].
Intestinal metaplasia involving the proximal stomach is 
histologically indistinguishable from intestinal metaplasia arising in 
Barrett's oesophagus but it has been claimed that Cytokeratin 20 and 7 
expression patterns can reliably discriminate between intestinal 
metaplasia in these two contexts[62]. Jovanovic et al [63] agreed that 
it was possible to distinguish intestinal metaplasia of the OGJ from Ck 7 
and 20 expression patterns. They demonstrated that the CK7/20 
immunophenotype of intestinal metaplasia at the gastric cardia resembled 
that of intestinal metaplasia in the gastric antrum and corpus, and 
differed from that seen in intestinal metaplasia of long segment 
Barrett's oesophagus.
Applying Ck7 and 20 antibodies to IM at the cardia discloses 
keratin phenotypes characteristic of both oesophageal and gastric 
intestinal metaplasia, and the oesophageal IM pattern is associated with 
GORD (i.e. SSBE). These antibodies could therefore prove helpful in 
evaluating the dysplasia risk to patients with intestinal metaplasia in 
the vicinity of the OGJ, by discriminating between SSBE and gastric 
intestinal metaplasia, which appear to be associated with different 
cancer risks.
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Tissue Type Site of graded 
cells
Ck7 staining Ck20 staining
Squamous Superficial -ve -ve
Deep -ve -ve
Squamous(adjacent Superficial Variable -ve
to Barrett's
mucosa) Deep -ve -ve
Barrett's Superficial +ve +ve
oesophagus(complete
and incomplete IM) Deep +ve -ve
Normal Gastric Superficial -ve +ve
(Cardiac, Fundic &
Antral) Deep -ve -ve
Gastric Complete Superficial -ve +ve
IM(Cardiac, Fundic
& Antral) Deep -ve +ve
Gastric Incomplete Superficial Variable Variable
IM(Cardiac, Fundic
& Antral) Deep Variable Variable
Table 2/1. Cytokeratin 7 and 20 staining patterns as described by Ormsby
et al [57] .
The objective of this part of the study was to confirm the 
distinctive Ck7/2 0 phenotype described as characteristic of Barrett's 
mucosa [57]. For this purpose we chose to examine only established LSBE, 
in order to avoid confounding our data with cases in which the 
differential diagnosis of SSBE v. gastric type IM at the OGJ was unclear.
Cytokeratin 7 and 20 patterns were examined throughout the length 
and different histological phenotypes of long segments of Barrett's 
mucosa and the corresponding gastric tissue for both non-dysplastic and 
dysplastic cases.
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Materials and Methods
Cytokeratin 7 and 20 immunostaining was performed on formalin-fixed 
paraffin embedded oesophageal and gastric biopsies from 50 patients 
diagnosed by endoscopy and biopsy with long segment Barrett's oesophagus.
1] Four micron sections dewaxed in xylene were rehydrated through 
graded alcohols to water.
2] Slides were washed in 3% aqueous hydrogen peroxide for ten 
minutes to eliminate endogenous peroxidase in the tissue, thus avoiding 
any confusion with the artificially attached peroxidase label, followed 
by a water wash.
3] Three antigen retrieval methods were compared: trypsin enzymatic 
digestion and microwave heating in either citrate or ethylenediamine 
tetraacetic acid (EDTA). Heating in EDTA (pH8) gave best results. EDTA in 
tris[hydroxymethyl]aminomethane (TRIS base) was brought to the boil in a 
microwaveable pressure cooker for 13 minutes prior to adding the sections 
which were then microwaved for a further 8 minutes ( 5 minutes of which 
was at full pressure) then left to cool in the antigen retrieval fluid 
for 20 minutes. This was followed by a water wash and 3 minute TRIS 
saline wash.
4] Horse serum (Vector) diluted 1:5 in TRIS saline was applied to 
the sections and left at room temperature for 15 minutes in order to 
block any non-specific background staining.
5] After blotting off the serum block, primary antibody diluted in 
antibody diluent (Dako) was applied to the sections and left at room 
temperature for 3 0 minutes and followed by a 3 minute TRIS saline wash. 
(Optimum primary antibody concentrations were determined by titration as 
follows; Ck 7 1 in 1000, CK 20 1 in 500)
6] Horse anti mouse biotin secondary antibody (Vector) was then 
applied for 30 minutes at room temperature.
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7] Avidin/ peroxidase labelled biotin (prepared half an hour in 
advance to allow complex formation) was applied for 30 minutes at room 
temperature followed by a 3 minute TRIS saline wash. The proportion of 
avidin to biotin is such that some binding sites on the avidin are left 
free to attach to the horse anti-mouse biotin.
8] Sections were then left in 3,3'-diaminobenzidine tetra chloride
| (DAB)/ H202/ TRIS saline solution for 10 minutes which enables the
j formation of visible brown reaction product at the antigenic site.
Ii
j
I
| 9] Sections were then left in Copper (II) sulphate 5-hydrate (BDH)/
I saline solution for 10 minutes, the copper ions turning the DAB a deeper
shade of brown.
i
I 10] After rinsing in water, the sections were counterstained with
haematoxylin (Sigma), dehydrated through graded alcohols, cleared in 
xylene and mounted in a resinous mountant.
The pattern of Ck7 and 20 positive staining was scored throughout
! the length of each oesophagus and at the OGJ. Each mucosal type at each
biopsy site was given a score for superficial and deep cell compartments 
rating staining intensity from zero to three; zero when there was no 
staining at all, one for weak staining, two for moderate and three for 
strong staining. This aimed to reflect the range of patterns of 
immunostaining seen in the oesophagus with these antibodies. The patterns 
of positive Ck staining were compared to those described by Ormsby et al 
[57], Specific intestinal metaplasia phenotype was ascertained from 
staining profiles with High Iron Diamine/ Alcian Blue (chapter 5).
Cytokeratin immunostaining was patchy and to deal with this issue 
the scoring protocol described above was modified by recording the range 
of staining intensity observed in the relevant tissue compartment. These 
ranges are given in the tables presenting the results below. Thus a 
score of "1-2" would imply weak to moderate staining; 2-3, moderate to 
strong; and so on. In the tables the weaker staining is on the 
horizontal axis and the stronger staining on the vertical axis. Entries
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on the diagonal (0-0,1-1,2-2,3-3) imply homogeneous staining of the given 
intensity.
In order to make the data as comprehensible as possible, the 
background in each cell in the tables has been shaded grey in proportion 
to the percentage of the scored biopsies in that group falling into that 
cell. This device was employed rather than giving the percentage figures 
in parentheses as it was felt that this would merely create a less 
graspable mass of data than the approach adopted.
Results
The results are presented in the graphs and tables which follow.
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CK 7 s ta in in g  p a tt e r n s  in  Squamous Epi t t ie liu m  N=!
z  oil
C K 20 s ta in in g  p a t t e r n s  in  S quam ou s E p i th e l iu m  N =9?
A B
Squamous epithelium, superficial Squamous epithelium, supetficial
3 7 1 3 1 3 0 0 0 0
2 16 1 4 2 o 0 1
1 19 3 ! 1 3 0
0 0
■ 0 1 2.... I 3 M 9? 0 1 2 3
| Squamous epithelium, deep
3 6 0 0 0
*> 8 0 0
1 7 0
0
'■I 9-1 0 1 2 3
| Squamous epithelium, deep
3 0 0 0 D
2 1 0 0
1 0 0
0
' 0 1 2 3
Graphs 2/1, Table 2/1, A and B. Cytokeratin 7 (A) and cytokeratin 
20 (B) expression in oesophageal squamous epithelium.
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Ck 20 expression is almost entirely negative in oesophageal 
squamous epithelium. Ck7 expression is variable, often negative, but may 
be positive, particularly in the differentiated superficial (luminal) 
compartment). This pattern differed somewhat from the Ck7-/Ck20- 
staining mentioned by Ormsby et al [62,63] in relation to native 
oesophageal squamous epithelium, but can be related to the Ck7 ±/Ck20- 
phenotype they mention in relation to squamous 'islands' often observed 
'floating' on Barrett's mucosa, and this intermediate phenotype may 
reflect a less determinate differentiation (as has been described in 
electron micrographs also).
A B
C K 2 0  s t a i n i n g  p a t t e r n s  i n  B a r r e t t ' s  M u c o s a  ( a l l  M u c i n  t y p e s )  N = 2 3 7
o.S?
- «/> 100 
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Z  O 50
CK 7 s t a i n i n g  p a t t e r n s  i n B a r r e t t ' s  Mu co s a ( a l l  M u c i n  t y p e s )  N=2 39
O  Q .  40 
z .O jo
A B
Barrett's mucosa, superficial Barrett's mucosa, superficial
3 57 26 34 54 3 46 12 15 66
2 13 9 38 2 30 9 42
1 3 5 1 9 5
0 0 0 3
N 2 0 1 2 3 M 2 37 0 1 2 3
| Barrett's mucosa, deep Barrett's mucosa, deep
3 79 22 16 33 3 19 0 0 1
2 33 7 31 2 33 0 0
1 1 1 1 16 1
0 0 0
N 22 3 0 1 2 3 M 221 0 1 2 3
Graphs 2/2, Table 2/2, A and B. Cytokeratin 7 (A) and cytokeratin 
20 (B) in intestinal-type Barrett's mucosa (all mucin phenotypes)
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Intestinal Barrett's mucosa as a whole shows rather similar 
patterns for both Ck7 and Ck20 in the superficial compartment, with 
marked heterogeneity of staining between cases. Heterogeneity of 
staining is also a marked feature for Ck7 in the deep compartment, with 
Ck2 0 more usually negative. While broadly in agreement with Ormsby's 
description of Ck7 positivity superficial and deep, and Ck20 positivity 
superficial only, heterogeneity is pronounced.
C K  7 s t a i n i n g  p a t t e r n s  in  B a r r e t t ' s  M u c o s a  ( T y p e  I )  N= 1 3 C K 2 0  s t a i n i n g  p a t t e r n s  i n  B a r r e t t ' s  M u c o s a  ( T y p e  I )  N = 1 3
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Type I IM, all loci, superficial
3 2 0 1 3
2 0 0 0
1 2 1
0 4
N 13 0 1 2 3
Type I IM, all loci, superficial
3 1 0 1
2 2 0
1 0 0
0 0
N 13 0 1 2 3
| Type I IM, all loci, deep Type I IM, all loci, deep
3 4 1 1 2 3 2 1 0 0
2 0 0 0 2 1 0 1
1 0 1 1 0 0
0 4 0
N 13 0 1 2 3 M 13 0 1 2 3
Graphs 2/3, Table 2/3, A and B. Cytokeratin 7 (A) and 
cytokeratin 2 0 (6) in Type I intestinal-type Barrett's mucosa.
The smaller number of cases with type I intestinal mucosa in 
Barrett's oesophagus make definitive evaluation difficult, but there is a 
suggestion that Ck7 is more likely to be negative in the deep 
compartment.
A B
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Z  O  20
A
Type IIA IM, all loci, superficial
3 21 9 9 14
2 6 5 13
1 7 4
0 9
N 97 0 1 2 3
Type IIA IM, all loci, deep
3 30 5 3 8
2 15 4 10
1 3 1
0 14
N 9 0 1 2 3
Graphs 2/4, Table 2/4, A and
20 (B) in Type IIA intestinal-type
B
Type IIA IM, all loci, superficial
3 15 4 5 32
2 9 3 25
1 3 2
0 1
N 99 0 1 2 3
] Type IIA IM, all loci , deep
3 8 1 0 2
2 14 0 1
1 4 1
0
N 92 0 1 2 3
. Cytokeratin 7 (A) and cytokeratin 
arrett's mucosa.
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Graphs 2/5, Tahle 2/5, A and B. Cytokeratin 7 (A) and cytokeratin 
20 (B) in Type IIB intestinal-type Barrett's mucosa.
These compare Ck7 and 20 phenotypes in type IIA and type IIB 
intestinal metaplasia. It will be seen that the staining distribution is 
virtually identical in the two cases, and that no possible distinction 
could be made in individual cases.
This particular group of cases did not include enough examples of 
gastric intestinal mucosa, H. pylori positivity or dysplasia for 
definitive analysis so this is not attempted.
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Chapter 3: Mucosal Phenotypes, Zoning and Oesophageal Dysplasia
Patients with Barrett's oesophagus usually present with a variable, 
sometimes asymmetrical length of columnar mucosa showing intestinal,
cardiac and fundic phenotypes in which occurs islands of squamous
epithelium [64]. However it is the specialised intestinal type mucosa 
which is thought to have the greatest risk of dysplastic development 
[40,41]. Some studies have commented on the appearance of zonation of 
the mucosal phenotypes in long segment Barrett's oesophagus with some 
mucosal phenotypes regularly seen more proximally to others but often a 
mixture of phenotypes is seen at a given level [64]
Some endoscopic studies have suggested that the upper limit of
columnar epithelium may extend proximally at successive examinations in 
the presence of continuing reflux, which suggests a process of creeping 
substitution of squamous by columnar mucosa [65], and with increasing 
severity of gastro-oesophageal reflux, the squamocolumnar junction shifts 
proximally, resulting in an increase in the length of cardiac-type 
columnar mucosa within the oesophagus [66]. In addition, studies using 24 
hour pH monitoring have shown that as acid exposure increases, the length 
of columar mucosa within the oesophagus significantly increases as well. 
However, Barrett's oesophagus may present as islands of columnar 
epithelium remote from the gastric cardia [25]. The tissue of origin for 
Barrett's metaplasia is not clear and three theories exist.
1] De novo metaplasia theory: stem cells of inflamed squamous 
mucosa in the exposed papillae are damaged, the resulting metaplasia in 
these cells produces Barrett's stem cells.
2] Transitional zone metaplasia theory: cells at the oesophago- 
gastric junction colonise the gastric cardia or distal oesophagus in 
response to noxious luminal agents.
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3] Duct cell metaplasia theory: stem cells located in the glandular 
neck region of oesophageal ducts might selectively colonise the 
oesophagus when mucosal damage occurs.
Chandrasoma [64] conducted a review of the oesophago-gastric 
junction in a large number of autopsies without known history of GORD. He 
determined that in most children and adults younger than 20 years of age 
the squamous epithelium of the oesophagus gave way directly to oxyntic 
mucosa of the gastric fundus with no interposed segment of cardiac type 
mucosa. Recognisable cardiac mucosa appeared in specimens from those 
older than 2 0 years and at a length of less than 1cm.
Cardiac mucosa is the simplest form of columnar epithelium with no 
specialised cells and it could be that cardiac mucosa in the oesophagus 
develops from reflux-induced injury to squamous epithelium. Both 
clinical and experimental animal evidence support this theory. Follow-up 
studies in patients who have undergone partial oesophagogastrectomy with 
an intrathoracic anastamosis of the oesophagus to the fundus of the 
stomach, which results in near constant bathing of the remaining 
oesophagus in refluxed gastric juice, have demonstrated over a period of 
months to years (mean time 8.2 years) the development of cardiac mucosa 
proximal to the anastamosis in what was squamous oesophagus.
Experimental evidence comes from a 197 0 study by Bremner et al [67] where 
dogs underwent stripping of the distal oesophageal squamous mucosa with 
or without cardioplasty to destroy the function of the lower oesophageal 
sphincter. They noted extensive squamous cell re-epithelialization in the 
animals without gastro-oesophageal reflux whereas squamous regeneration 
was absent or minimal in animals with cardioplasty induced reflux in 
which the oesophagus was replaced by a columnar epithelium that lacked 
submucosal glands and parietal cells equivalent to human cardiac mucosa.
The murine antibody DAS-1, which stains 'specialized' (intestinal- 
type) columnar mucosa, also reacts positively with cardiac mucosa and on 
repeat biopsies histological evidence of intestinalization later 
developed in 6 of 7 patients [1]. This could suggest that cardiac mucosa
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is the precursor of intestinalized columnar epithelium as postulated by 
De Meester et al [23].
Analysing patterns of mucosal development in the columnar lined 
oesophagus could improve our understanding of the early stages of 
Barrett's oesophagus, the precursors in the metaplastic, dysplastic 
sequence towards adenocarcinoma in this disease.
Materials and methods
Thirty-two consecutive patients with biopsy-proven long segment 
Barrett's oesophagus attending Glasgow Royal Infirmary were recruited as 
part of a study of telomerase activity in Barrett's mucosa, not part of 
this study. Apart from five newly diagnosed patients, all were already 
undergoing annual endoscopy and biopsy with three biopsies for every 2cm 
of columnar-lined oesophagus (every 1cm in patients with a previous 
diagnosis of dysplasia). Patients with previously diagnosed invasive 
adenocarcinoma were excluded. In all, the 32 patients had experienced 
152 endoscopies with biopsy, including 77 before the 32 study 
endoscopies, and 43 after. All patients had more than 3 cm of columnar 
mucosa in the distal tubular oesophagus. Median length of Barrett's 
oesophagus was 8 cm (range 3 - 1 6  cm). Mean and median age of patients at 
the time of the study endoscopy was 64 and 70 years (range 37 to 84). 
There were 24 males and 8 females. Dysplasia was identified in at least 
one biopsy in ten of these patients, and indefinite changes not amounting 
to confirmed dysplasia in a further seven patients. The study was 
approved by Glasgow Royal Infirmary ethics committee and patients gave 
informed written agreement to participate.
Biopsy protocol
At each endoscopy, three biopsies were taken for histology each 
from the following locations: original squamous mucosa proximal to the 
Barrett's segment, columnar side of the sqpaamo-columnar junction (Z 
line), Barrett's segment every 2cm, anatomical oesophago-gastric
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junction(defined by the most proximal gastric folds), gastric corpus and 
antrum. All biopsies were fixed overnight in 4% neutral buffered 
formaldehyde, embedded in paraffin wax, and four micron sections cut at 
three histological levels. Dewaxed sections were stained with 
haematoxylin-eosin and three biopsies each from a total of 268 sites 
(n=794) were examined histologically. In addition, histological review 
was performed of all oesophageal and gastric sites previously (n=488) and 
subsequently (n=401) biopsied, representing in all 1057 sites and 3171 
individual mucosal biopsies.
Biopsy review
One pathologist with an interest in Barrett's oesophagus (JJG) was 
responsible for initial reporting of all biopsies from all endoscopies. 
Subsequently, all biopsies were reviewed by the same pathologist 'blind' 
to his original report. Presence or absence of the following mucosal 
types was recorded for each biopsy. 1. Full-thickness squamous 
epithelium. 2. Immature squamous 'islands' overlying glandular mucosa.
3. 'Specialised' Barrett's mucosa, defined by goblet cells. 4. Mucosa 
resembling gastric cardia, without goblet cells or oxyntic cells. 5. 
'Cardio-oxyntic mucosa with oxyntic cells, or fully-developed fundic 
:mucosa. 6. Antral mucosa (in gastric biopsies). Intestinal metaplasia 
in biopsies from gastric sites was separately recorded.
Glandular dysplasia was evaluated, also by JJG, using published 
criteria [17,68] in conformity with the Vienna classification [69,70] in 
the following groups: 1. No dysplasia. 2. Mild changes, possibly 
reactive: indefinite for dysplasia. 3. Definite dysplasia of mild or 
moderate severity: low grade dysplasia. 4. Severe dysplasia /
adenocarcinoma in situ: high grade dysplasia. While category 4 may also 
include biopsies in which invasion is suspected, our series did not 
include such biopsies. Phenotype of the dysplastic mucosa and biopsy 
level were also recorded. At any biopsy site the most severe dysplasia 
category was recorded and analysed.
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Published studies show good inter- and intra-observer agreement in 
recognising high grade glandular dysplasia in Barrett's oesophagus 
[71,72], but less robust discrimination between no dysplasia, indefinite 
and low grade dysplasia. To evaluate the observer's consistency of 
dysplasia grading in this study, all biopsies were re-scored 'blind' to 
the original reading, after a minimum delay of six months. The review 
dysplasia coding was compared with the grading originally assigned. If 
these were in agreement, that grading was accepted. If discrepant, a 
third 'blind' review was undertaken, and final allocation of dysplasia 
grade was based on the majority reading. Reproducibility of dysplasia 
grading was evaluated by comparison of the first and second overall 
readings for each biopsy group from a specific site. While application 
of diagnostic criteria has been reviewed with histopathologist colleagues 
in the same and other institutions, inter-observer agreement was not 
evaluated formally.
Derived calculations and statistical analysis
The spatial distribution of mucosal phenotypes in Barrett's 
oesophagus was examined by graphing the percentage of biopsy groups in 
which each mucosal phenotype was present as a function of the distance 
from the Z line to the anatomical oesophago-gastric junction. The 
distance along each Barrett's oesophagus was also expressed as a
percentage, to compensate for the variable length of Barrett's oesophagus
in different patients. This was done by mapping the percentage of 
biopsies in which a particular mucosal type was present in each 
centimetre of a particular Barrett's oesophagus to the corresponding 
section of the graph, and averaged for all 32 patients. The mean
percentage was calculated for every length centile by summation (£) over
all 32 patients as SflOOnx/L)/ E(100n2/L), where nx is the number of 
biopsy groups containing the feature in question, n2 the total number of 
biopsy groups, and L is the length of each Barrett's oesophagus in 
centimetres. This strategy gives equal weight to all biopsies. Zonal 
distribution of dysplasia was examined identically, taking nx as the
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number of biopsy sites found to be dysplastic, and n2 as the number of 
sites in which 'specialised' Barrett's mucosa was confirmed (because 
dysplasia was almost exclusively associated with the intestinal 
phenotype).
The kappa statistic [73] was calculated as a measure of agreement 
using Analyse-It version 1.48 (Analyse-It Co, Leeds, UK) in Microsoft 
Excel 97. Group comparisons were made using Fisher's Exact Test.
Results
Repeatability of dysplasia reading
To demonstrate reproducibility of dysplasia grading in this biopsy 
series, repeat scores are presented for individual biopsy sites (N=612) 
in table 3/1. The overall kappa score (0.62) represents good agreement.
There is most discrepancy between no dysplasia and indefinite for 
dysplasia, and least between low and high grade dysplasia.
Second
reading
First reading
No dysplasia Indefinite Low grade 
dysplasia
High grade 
Dysplasia
No dysplasia 469 34 8 0
Indefinite
dysplasia
20 15 5 0
Low grade 
dysplasia
9 6 46 0
High grade 
dysplasia
0 0 6 21
Table 3/1. Repeatability of dysplasia grading by Dr J.J. Going in 612 
individual Barrett's biopsy sites. Overall kappa score = 0.62 (good 
agreement).
Merging 'no dysplasia' with 'indefinite for dysplasia' creates 3 
categories (no definite dysplasia, low grade dysplasia, high grade 
dysplasia) with a kappa score representing excellent repeatability 
(0.79). Although changes suspicious of invasion are often associated
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with high-grade dysplasia, such changes were not identified in these 
patients, probably because only five of our patients were recently 
diagnosed. The others had been biopsied previously, and patients with 
evidence of invasion excluded.
Zonal distribution of mucosal types in Barrett's oesophagus
In order to investigate the zonal distribution of mucosal types in 
Barrett's oesophagus, biopsies were taken for histology from the 
following locations: original squamous mucosa proximal to the Barrett's 
segment, columnar side of the squamo-columnar junction (Z line), 
Barrett's segment every 2cm, anatomical oesophago-gastric junction 
(defined by the most proximal gastric folds), gastric corpus and antrum. 
Presence or absence of the following mucosal types was recorded for each 
biopsy. 1. Full-thickness squamous epithelium. 2. Immature squamous 
'islands' overlying glandular mucosa. 3. 'Specialised' Barrett's 
mucosa, defined by goblet cells. 4. Mucosa resembling gastric cardia, 
without goblet cells or oxyntic cells. 5. Cardio-oxyntic mucosa with 
oxyntic cells, or fully-developed fundic mucosa. 6. Antral mucosa (in 
gastric biopsies). Intestinal metaplasia in biopsies from gastric sites 
was separately recorded.
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Figure 3/1. Data for 32 patients with long segment Barrett's 
oesophagus. These graphs indicate the mean probability (expressed as a 
percentage) of different mucosal types being present in Barrett's 
oesophagus as a function of normalised anatomical level, on the vertical 
axis, from the Z line proximally (top), down to, but not including, the 
anatomical oesophago-gastric junction distally (bottom). The grey shaded 
area in each box shows how often that particular component is found at 
that level. The five boxes represent a, full thickness squamous 
epithelium; b, squamous islands over glandular mucosa; c, 'specialised', 
intestinal-type Barrett's mucosa; d, cardiac type mucosa; and e, cardio- 
oxyntic or fundic mucosa.
This analysis showed a pronounced proximal-to-distal zonation of 
mucosal phenotype in long segment Barrett's oesophagus which was 
reflected in the probability of detecting different mucosal types at 
different levels in the Barrett's segment. Figure 3/1 is a more detailed 
graph of the mean probability for all 32 patients of different mucosal 
types being present in Barrett's oesophagus as a function of anatomical 
level from the Z line to the most distal Barrett's oesophagus, excluding
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the oesophago-gastric junction. Table 3/2 is an overview of the data 
looking at Barrett's oesophagus by thirds.
Location
Squamous
Mucosa
Squamous
Islands
Specialised
Barrett’s
Mucosa
Cardiac
Mucosa
Fundic-
like
Mucosa
Z Line 32 10 31 7 0
100% 31% 97% 22% 0%
Z Line and upper 32 14 32 10 2
third 100% 44% 100% 31% 6%
Middle third 19 18 32 17 5
59% 56% 100% 53% 16%
Lower third 16 15 32 27 23
50% 47% 100% 84% 72%
OG junction 7 8 18 23 30
22% 25% 56% 72% 94%
Table 3/2. Zonation of mucosal type in 32 cases of Barrett's 
oesophagus. Columns show the number and percentage of cases in which 
different mucosal types were present at various levels including the Z 
line alone and the upper, middle and lower third of the Barrett's 
segment.
Full thickness squamous epithelium was often detectable in the 
upper third of the Barrett's segment, diminishing in frequency distally. 
Superficial squamous islands overlying glandular mucosa were present less 
often but at all levels without much variation in frequency. Cardiac­
like mucosa occurred at all levels in Barrett's oesophagus, but more 
often distally. Oxyntic differentiation hardly occurred above the lower 
third. In this location some biopsies may actually derive from native 
gastric mucosa, but there is no doubt that oxyntic differentiation in an 
otherwise cardiac-like mucosa can be found in the true oesophagus, 
confirmed by the presence of oesophageal submucosal glands or their 
diucts. In contrast, 'specialised' intestinal-type Barrett's mucosa was 
likely to be found at all levels in every case, confirming its ubiquitous 
status in Barrett's oesophagus. Equally characteristic in individual 
ciases was the occurrence of several different mucosal phenotypes at a 
single anatomical level: i.e. mucosal zonation in Barrett's oesophagus is
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present but does not create horizontal bands of uniform mucosal type, but 
a patchwork of mucosal types varying in proportion with anatomical level.
Dysplasia and mucosal phenotype
Our data confirm that dysplasia in Barrett's oesophagus is 
especially likely to occur in 'specialised' intestinal type-mucosa, and 
not in other mucosal types [74,75,76]. Definite dysplasia, low or high 
grade, was present at 87 sites biopsied; in 85 of these the dysplasia was 
in continuity with histologically confirmed 'specialised' intestinal 
type, found at 616 sites (14%) and only two dysplastic sites were in 
continuity with histologically confirmed cardiac-type mucosa, found at 
156 oesophageal sites (1.3%)(P<0.00001).
Zonal distribution of dysplasia
This was examined in the same way as the zonal distribution of 
mucosal phenotype. Figure 3/2 shows the average probability of dysplasia 
for ten cases in which there was definite dysplasia, and a further seven 
cases indefinite for dysplasia. Although some fluctuation in the 
probability of dysplasia being present was observed, there was no 
evidence of any major proximal to distal trend.
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Figure 3/2. This graph plots the average probability (as a 
percentage on a scale of 0 to 100) of dysplasia being present in 
'specialised' intestinal Barrett's mucosa as a function of normalised 
anatomical level. Data are averaged for ten patients with long-segment 
Barrett's oesophagus and definite biopsy-proven dysplasia, and seven 
patients indefinite for dysplasia. There is no evidence of any 
significant proximal-to-distal gradient in dysplasia frequency. Light 
grey area represents definite dysplasia, darker grey biopsies indefinite 
for dysplasia.
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Chapter 4: DNA Replication Licensing Proteins
In normal oesophageal squamous epithelium, stem cells divide slowly 
in the basal layer giving rise to daughter cells which supply a 
population of mature cells at the luminal surface [77]. In Barrett's 
oesophagus the proliferative compartments are similar to those in gastric 
mucosa, with maximum proliferation in a zone beneath the mucosal surface 
[78] .
Organization of proliferation and differentiation zones appears to 
break down in dysplastic epithelia. This failure could potentially 
identify tissue at a preneoplastic stage with proliferating and atypical 
cells identifiable on the luminal surface, (as seen characteristically in 
dysplastic mucosae), if a suitable marker of proliferative capacity was 
available. The Mini-chromosome maintenance (Mem) proteins are candidates 
for this role.
Initiation of DNA replication in eukaryotic cells is a highly 
regulated process that requires the ordered assembly of many proteins at 
multiple origins of DNA replication to form a competent prereplicative 
chromosomal state [79-82]. The eukaryotic initiator proteins form the 
origin of replication complex (ORC) where proteins interact to form a 
pre-replicative complex (pre-RC). This can only happen at certain stages 
of the cell cycle [79]. Mini-chromosome maintenance proteins form an 
essential part of this complex with Cdc6 being required for their loading 
onto the ORC. [79-82]. The assembly of the pre-RC containing: ORC, cell 
division cycle protein 6(Cdc6) and Mem proteins, occurs at a point 
defined by cyclin CDK activity [83]. After initiation a post-RC is formed 
and cyclin CDK activity blocks the assembly of the pre-RC. Competence to 
initiate DNA replication in vitro arises suddenly following release from 
quiescence coinciding with maximum Cdc6 accumulation and binding of the 
Mem protein complex to chromatin. Mem proteins become bound to chromatin 
during late mitosis and remain there until they are gradually removed as 
S phase progresses [82], so newly replicated sections of chromatin are
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free of Mem proteins and therefore cannot replicate during the same cell 
cycle. It follows that Mem expression is required for cell proliferation 
potential to ensure DNA replication occurs only once per cell cycle [84],
EARLY G 1
G 1
ORC
l a t e g i ^ - ^  Pre-RC
S PHASE 4 t
SB
G2 Post-RC
Figure 4/1. A model for the role of Mem proteins in the control of 
DNA replication. It shows the ordered assembly of the Pre-RC containing: 
ORC, Cdc6p and the Mem proteins. After initiation of replication a Post- 
RC is formed. The cycle of assembly and disassembly of the initiation 
proteins has a role in blocking the re-firing of origins in the same cell 
cycle.
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The Mem proteins were first identified in a screen for mutations 
that caused defects in the maintenance of plasmids in yeast [80,85].
There are six Mem proteins (labelled 2-7) and they have a central core of 
homology [85]. Released nucleoplasmic Mem proteins are found as large 
multiprotein complexes which have the tendency to disintegrate into more 
stable subcomplexes one of which is a dimer of Mem 3 and 5, another a 
trimer of Mem 4, 6 and 7, with Mem 2 usually found loosely associated 
with these subcomplexes. Mem 5 is quite easily separated from other Mem 
proteins so is described as a peripheral protein, Mem 4 and 6 associate 
very strongly in what is thought to be a core complex, Mem 4 being 
essential for Mem 2 to bind to this core complex [86]. During late 
mitosis there is a brief window when the Mem proteins are able to bind to 
chromatin, during this period they associate to a form that has chromatin 
binding potential, a step that may be initiated by dephosphorylation of 
the Mem complex [87].
Immunodepletion of Mem proteins from Xenopus extract was found to 
block DNA synthesis [88] . Reduced dosage of the Mem proteins allowed 
replication but prevented completion of S phase, resulting in DNA damage 
and genomic instability. It could be that when Mem protein levels are 
reduced, only a few active Mem complexes are assembled, sufficient to 
fire a subset of origins but not enough to complete genome replication.
The Mem proteins are bound to chromatin at levels that far exceed 
the number of active replication origins [89], so they probably have 
functions in addition to replication licensing. They may aid replication 
movement as they have a conserved DNA dependent ATPase domain shared with 
helicases or they could be involved in the assembly or disassembly of 
replisomes at initiation sites or in the assembly of replication 
factories composed of large numbers of replisomes [83,85,87,89],
By isolating the soluble cellular proteins in urine, an immunoassay 
assay of Mcm5 proteins has been used sucessfully to detect cancers of the 
urinary tract [90]. Additionally, anti-Mcm5 antibodies can improve the 
Papanicolaou smear test for cervical dysplasia and neoplasia [91],
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therefore it seemed appropriate to examine their pattern of expression in 
the non-dysplastic and dysplastic oesophagus.
Chapter 4: Materials and Methods
We examined cell proliferation in non-dysplastic and dysplastic 
squamous epithelium and Barrett's mucosa in biopsies by immunostaining 
with antibodies directed against Ki67, and replication licencing with 
antibodies against minichromosome maintenance proteins 2 and 5, donated 
by Professor Gareth Williams (Cambridge).
Immunohistochemical staining was carried out as described (chapter 
2). The Ki67 antibody was clone MIBl from DAKO (a mouse monoclonal). The 
anti-Mem antibodies were rabbit polyclonals. After titration, the optimum 
primary antibody concentrations were as follows: Ki 67 1/100, Mem 2 
1/4000, Mem 5 1/ 4000. Biopsies from a total of 77 patients were 
studied: formalin fixed, paraffin embedded tissue blocks were cut at 4|0m 
and fixed onto silane coated slides. Patients were from cohorts 
undergoing diagnostic endoscopy enrolled in a programme of yearly 
surveillance of Barrett's oesophagus, or had surgical resection of 
Barrett's associated oesophageal carcinoma.
Dysplastic changes were assessed on haematoxylin and eosin stained 
sections of paraffin embedded endoscopic biopsies and tissue blocks from 
resection specimens. These were shown to represent a range of 
morphologies from normal oesophageal squamous epithelium through low and 
high grade squamous dysplasia, to invasive squamous carcinoma (tables 
4/1-2). Similarly, examples of Barrett's mucosa without dysplasia, low 
grade dysplasia and high grade dysplasia in Barrett's mucosa and invasive 
Barrett's adenocarcinoma were selected.
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WITHOUT BARRETT'S OESOPHAGUS (25) WITH BARRETT'S OESOPHAGUS (45)
NO SQUAMOUS DYSPLASIA (13) NO DYSPLASIA (25)
LOW GRADE SQUAMOUS DYSPLASIA (3) LOW GRADE DYSPLASIA (10)
HIGH GRADE SQUAMOUS DYSPLASIA (6) HIGH GRADE DYSPLASIA (8)
LOW & HIGH GRADE SQUAMOUS DYSPLASIA 
(3)
LOW AND HIGH GRADE DYSPLASIA (2)
4 ALSO HAD INVASIVE SQUAMOUS 
CARCINOMA
4 ALSO HAD INVASIVE ADENOCARCINOMA
Table 4/1. The number of biopsies immunostained from different 
tissue categories.
Category Ki67 Mcm2 Mem 5
Squamous, non-dysplastic 53 54 51
Low grade squamous dysplasia 5 5 3
High grade squamous dysplasia 11 11 7
Invasive squamous carcinoma 6 6 5
Barrett's mucosa 34 35 33
Low grade Barrett's dysplasia 19 19 18
High grade Barrett's dysplasia 10 7 9
Invasive Barrett's adenocarcinoma 4 4 4
Table 4/2. Number of biopsies stained for Ki67, Mcm2 and Mcm5 in 
different categories.
Immunostaining of cell nuclei was scored positive or negative using 
a semi-quantitative scoring scheme. Intensity of staining did not vary 
much and was not scored. Four compartments were recognised in the 
squamous epithelium; (l)the most basal single layer of cells and the 
thickness of the epithelium above that divided into (2)parabasal,
(3)middle and (4)luminal thirds. In Barrett's mucosa four strata were 
also defined; (4)the surface epithelium between crypts, the underlying 
crypts divided into (3)upper and (2)lower halves and(l)the deepest layer, 
a differentiated glandular zone (fig 4/2).
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Figure 4/2. Mem 2 expression in squamous epithelium (A) and Barrett's 
mucosa (B), showing the four scoring compartments.
These compartments corresponded to known areas of cell 
proliferation, as defined by Lauwers et al (90), and within each 
compartment the estimated percentage of positive cells was allocated to 
scoring bands as follows: 0: no staining 1: <10% +ve stained cells. 2: 
10-30% +ve stained cells. 3: 30-70% +ve stained cells. 4: 70-90% +ve 
stained cells. 5: >90% +ve stained cells. 6: 100% +ve stained cells. 
Actual cell counts were not attempted.
Statistical significance of the differences between staining scores 
for the same tissue compartments in different biopsies or within the same 
biopsy was established using a Mann-Whitney test (table 4/3).
Results
Both the Mem 2 and the Mcm5 antibodies yielded clear nuclear 
staining although the Mcm5 staining was less clean, with some staining of 
cytoplasm and cell membranes in the glandular mucosae. Ki67 with 
monoclonal antibody MIB-1 yielded clean nuclear staining as expected.
In the non-dysplastic mucosae (both squamous and glandular) both 
showed maximal proliferation in the expected compartments, suprabasal in 
the case of squamous epithelium and in the lower crypt in Barrett's 
mucosa. Expression of both the cell cycle marker Ki67 and the 
replication licensing proteins were downregulated in the mature
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compartments as expected, i.e. towards the surface of the squamous 
epithelium and on the surface and in the deep glands in the glandular 
mucosae. In the presence of dysplasia, however, this spatial 
organization of the mucosae broke down, with persistence of proliferation 
and especially persistence of replication licensing into compartments 
which would not normally be so licensed (figures 4/1, 4/2). Figure 4/3 
has been constructed to summarise a large body of data for squamous and 
Barrett's mucosae with no dysplasia, low grade dysplasia, or high grade 
dysplasia. Most striking feature in both squamous and Barrett's mucosa 
is the progressively increasing expression of Ki67 and especially of the 
Mem proteins on the mucosal surface with increasing dysplasia.
Ki 67 Mcm5 Mcm2
Squamous
epithelium
Normal v LGD P < 0.0001 P < 0.0005 P < 0.0029
Normal v HGD P < 0.0001 P < 0.0001 P < 0.0001
Barrett's 
Mucosa
Normal v LGD P < 0.0001 P < 0.0001 P < 0.0001
Normal v HGD P < 0.0001 P < 0.0001 P < 0.0001
Table 4/3. Univariate analysis of significance of differences in Ki67 
and Mem protein expression between normal and dysplastic epithelium on 
the surface of oesophageal squamous and Barrett's mucosa.
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Figure 4/3. Distribution of proliferating cells in Barrett's mucosa 
without dysplasia (A) and with high grade dysplasia (B). 
Immunohistochemistry for Ki67 (monoclonal antibody MIB-1). Distinct 
proliferation and differentiation compartments in the non-dysplastic 
mucosa are lost in dysplasia.
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Figure 4/4. Distribution of DNA replication licensed cells in non- 
dysplastic Barrett's mucosa (A) and low-grade Barrett's mucosa (B). In 
the absence of dysplasia cells lose their replication as they migrate on 
to the mucosal surface, but retain that capability in the dysplastic 
mucosa. Notice the abrupt transition between licensed and unlicensed 
cell populations on the right side of the lower figure.
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None None
Figure 4/5. Expression of minichromosome maintenance proteins 2 
and 5 and Ki67 in squamous epithelium (left, pinkish background) and 
Barrett's mucosa (right, greenish background). Each of the 18 small 
plots indicates the distribution of one marker in four layers from most 
superficial on the left (a) to deepest (d) on the right, as described in 
the methods section. All the plots in one row are for the same marker 
protein and the dysplasia status of the mucosa is indicated at the foot 
of each column. Large blobs represent medians; bars the interquartile 
range; and small circles the range in each case.
Although persistent expression of Mem proteins is a very 
characteristic feature of dysplastic squamous and Barrett's epithelium, 
this is clearly not an absolute feature of the neoplastic state, as we 
did observe cases in which viable but Mcm-negative tumour cells were 
present in both invasive adenocarcinoma and invasive squamous carcinoma 
of the oesophagus.
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Chapter 5: Mucin Phenotypes
Based on the anticipated risk of malignancy, the spectrum of 
Barrett's mucosa can be divided into the following two types [92]: a) 
Columnar epithelium without specialised intestinal metaplasia composed of 
columnar mucosa, but lacking goblet cells, b) Columnar epithelium with 
specialised intestinal metaplasia including goblet cells and columnar 
non-goblet cells. Specialised intestinal metaplastic epithelium in the 
oesophagus can further be subdivided by the mucin profile and appearance 
of the columnar cells [19,20]:
a) Complete intestinal metaplasia (type 1), in which the columnar 
cells resemble normal enterocytes without mucus secretion and with well- 
developed brush borders. This type of intestinal metaplasia is 
relatively uncommon in Barrett's mucosa.
b) Incomplete intestinal metaplasia (also known as type 2A), in 
which columnar cells secrete neutral mucins or sialomucins, but not
Si^ lpkoMMO/JS and there is an incomplete or absent brush border. The 
goblet cells may contain sulphomucins.
c) Incomplete intestinal metaplasia (type 2B), in which columnar 
cells secrete sulphomucins.
Adenocarcinoma of the stomach is often associated with type 2B 
intestinal metaplasia of the adjacent mucosa and histological 
identification of goblet cells is regarded as the hallmark of Barrett's 
oesophagus patients at higher risk of adenocarcinoma and therefore 
candidates for endoscopic surveillance [18-20,92]. Sulphomucins in 
columnar cells have also been considered a marker of dysplasia in 
Barrett's oesophagus [18]. The role of the columnar non-goblet cells in 
the progression towards malignancy is not yet clarified but they have 
been shown to express the same intestinal enzymes as neoplastic cells of 
associated adenocarcinomas [92].
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Figure 5/1. Different IM types. (A) : Type 1. Note brush, border 
(arrow).(B):Type Ila. High iron diamine staining (sulphomucins) confined 
to goblet cells.(C):Type lib. Sulphomucin-positive columnar cells are 
numerous.
Figure 5/2. Incomplete (A) and complete (B) intestinal metaplasia. 
Strongly alcianophilic goblet cells and weakly alcianophilic columnar 
cells are present in incomplete intestinal metaplasia. This could be type 
IIA or type IIB. The brush border of the enterocytes and their lack of 
cytoplasmic mucin are characteristic of complete intestinal metaplasia.
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There is a range of routine stains available to identify mucin 
profiles of the columnar lined oesophagus. Periodic acid - Schiff stains 
neutral mucins of both gastric fundic and cardiac types of Barrett's 
mucosa [20]. Alcian blue at pH 2.5 stains acidic mucins (sialomucins and 
sulphomucins) and can be combined with high iron diamine staining for 
sulphomucins.
We established sulphomucin profiles of the columnar cells in 
intestinal metaplasia of oesophageal and gastric biopsies by the high 
iron diamine/Alcian blue staining technique on non-dysplastic and 
dysplastic tissue to investigate whether an association could be detected 
between the type 2B incomplete intestinal metaplasia phenotype and early 
events in the progression to oesophageal adenocarcinoma.
Chapter 5: Materials and Methods
Sections of 1240 formalin-fixed paraffin-embedded gastric and OGJ 
biopsies taken from patients identified as showing intestinal metaplasia 
on routine pathology reports were stained using a High Iron 
Diamine/Alcian Blue technique to establish their mucin phenotype and this 
was subsequently compared to the presence and degree of dysplasia present 
in these sections.
High Iron Diamine/Alcian Blue staining protocol
1] Sections were dewaxed through xylene, rehydrated through graded 
alcohols and washed in water.
2] Sections left for 24 hours in a solution of freshly prepared 
N,N-dimethyl-m-phenylene diamine dihydrochloride (Sigma) and N,N- 
dimethyl-p-phenylene diamine hydrochloride (Sigma) dissolved in distilled 
water and 40% ferric chloride (BDH).
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3] Sections were rinsed rapidly in water and left in Alcian Blue 
(Sigma) for 1 hour.
4] Sections were then dehyrated rapidly through graded alcohols, 
cleared in xylene and mounted in a resinous mountant.
Scoring
Type 1 complete intestinal metaplasia was indicated by surface 
columnar cells which resemble normal enterocytes with well developed 
brush borders.
Type IIA intestinal metaplasia was defined by blue or blue-black 
staining goblet cells containing sialomucins or sulphomucins scattered 
among columnar cells containing either neutral mucins or blue staining 
sialomucins, with no evidence of a brush border or high iron diamine 
staining.
Type IIB intestinal metaplasia was defined black/blue staining of 
columnar cells, indicating the presence of sulphomucins, with goblet 
cells containing either sialomucins, sulphomucins, or both.
Reproducibility of scoring was tested by independent allocation of 
a random sample of 43 biopsies to the types indicated above (I/IIA/IIB) 
by LN and also by the supervisor (JJG). The Kappa statistic was 
calculated from the resulting 3x3 contingency table as a measure of 
agreement.
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Results
Reproducibility of mucin phenotyping♦
Forty-three biopsies were scored independently by LN and JJG. The 
3x3 contingency table (5/1) represents the results of this exercise:
Classification of mucin phenotype by JJG
I IIA IIB
Classification 
of mucin 
phenotype by LN
I 3 3 0
IIA 1 17 5
IIB 0 0 14
Table 5/1. Comparison of classification of mucin phenotype by LN and JJG
The kappa score for these values is 0.56, which indicates 
reasonable if not outstanding agreement. While the agreement could have 
been better, agreement was good enough for the data to be analysed, 
therfore no attempt was made to improve it.
Mucin phenotype, dysplasia and neoplasia (all sites)
Initially the distribution of mucin phenotypes was looked at as a 
function of the presence and degree of dysplasia at all sites. The 
following categories were extracted from the pathology reports: 0, no 
dysplasia or atypia. 1, reactive atypia. 2, indefinite for dysplasia. 3, 
low grade dysplasia, 4, high grade dysplasia. 5, invasive carcinoma. The 
following table shows the raw data analysed for all biopsies with the 
worst atypia/neoplasia score of the biopsy taken from the original 
pathology report:
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Worst atypia/neoplasia score
Mucin 0 1 2 3 4 5
I 136 13 0 0 0 5
II (NOS) 1 0 0 0 0 0
I/IIA 83 21 1 2 0 5
I/IIB 27 12 3 1 0 4
IIA 341 89 26 24 6 11
IIB 332 169 59 58 19 13
Table 5/2. Mucin phenotypes for all biopsies stratified by atypia.
This table can be simplified by combining groups in order to show 
how many biopsies contain the relevant types of metaplastic mucosa:
Worst atypia/neoplasia score
Mucin 0 1 2 3 4 5
I 246 46 4 3 0 14
IIA 424 110 27 26 6 16
IIB 359 181 62 59 19 17
Table 5/3. Mucin phenotypes for all biopsies stratified by atypia. Some 
biopsies are represented in row 1 and row 2 because both types of IM were 
present. Type IIB IM appears only in row 3.
or
Worst atypia/neoplasia score
Mucin 0 1 2 3 4 5
I 246 46 < 7 > 14
IIA 424 110 < 59 > 16
IIB 359 181 < 140 > 17
Table 5/4. As 5/2, but combining dysplasia groups.
or
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Worst atypia/neoplasia score
Mucin 0 1 2 3 4 5
I 292 (264) < 7(40) > 14(9)
IIA 534(513) < 59(77) > 16(18)
IIB 540(588) < 140(89) > 17 (20)
Table 5/5. As 5/3, but combining the groups with no atypia or reactive 
atypia and the dysplasia groups. Expected values are given in brackets.
Inspection of the pooled data (table 5/4) shows that the 
distribution of IM phenotypes does not differ significantly from expected 
in this large biopsy series for dysplasia groups 0 and 1 (no dysplasia, 
reactive atypia) or for the cancer group (5), but there is a strikingly 
non-random distribution within the dysplastic biopsies (dysplasia groups 
2-4). %2 = 72.165 (d.f. =2, P < 0.0005). This very large %2 value is
almost entirely due to the deficiency of type I IM and the excess of type 
IIB IM in this group.
Without getting involved in excessive subgroup analysis, it seemed 
appropriate to repeat this analysis separating the 812 true oesophageal 
biopsies from gastric sites and the OG junction (N = 649).
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Mucin phenotype, dysplasia and neoplasia (oesophagus)
Worst atypia/neoplasia score
Mucin 0 1 2 3 4 5
I 27 7 0 0 0 0
I/IIA 14 3 0 0 0 0
I/IIB 8 5 2 0 0 1
IIA 148 57 23 22 3 2
IIB 224 139 54 51 16 5
Table 5/6. Mucin phenotypes for oesophageal biopsies by atypia.
Worst atypia/neoplasia score
Mucin 0 1 2 3 4 5
I 49 25 2 0 0 1
IIA 162 60 23 22 3 2
IIB 232 144 56 51 16 6
Table 5/7. Mucin phenotypes for oesophageal biopsies stratified by 
atypia. Some biopsies are represented in row 1 and row 2 because both 
types of IM were present. Type IIB IM appears only in row 3.
Worst atypia/neoplasia score
Mucin 0 1 2 3 4 5
I 49 25 < 2 > 1
IIA 162 60 < 48 > 2
IIB 232 144 < 123 > 6
Table 5/8. As 5/7, but combining dysplasia groups.
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Worst atypia/neoplasia score
Mucin 0 1 2 3 4 5
I 74(60) < 2 (16) > 1
IIA 222 (214) < 48(55) > 2
IIB 376 (397) < 123(102) > 6
Table 5/9. As 5/8, but combining the groups with no 
atypia and the dysplasia groups. Expected values are 
except where the expected numbers are <5.
atypia or reactive 
given in brackets
Using the figures in table 5/9 but omitting column 5 (because the 
expected values are all <5) gives %2 = 21.40, and again this large %2 
value (d.f. =1, P < 0.0005) is almost entirely due to the deficiency of 
type I IM and the excess of type IIB IM in the dysplasia group.
Finally the gastric biopsies were examined (including the 
oesophago-gastrie junction and cardia, in more or less equal numbers).
Mucin phenotype, dysplasia and neoplasia (gastric)
Worst atypia/neoplasia score
Mucin 0 1 2 3 4 5
I 109 6 0 0 0 5
I/IIA 69 18 1 2 0 5
I/IIB 19 7 1 1 0 3
IIA 193 32 3 2 2 9
IIB 109 30 5 7 3 8
Table 5/10. Mucin phenotypes for gastric biopsies by atypia.
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Worst atypia/neoplasia score
Mucin 0 1 2 3 4 5
I 197 31 2 3 0 13
IIA 266 50 4 4 2 14
IIB 128 37 6 8 3 11
Table 5/11. Mucin phenotypes for gastric biopsies stratified by atypia. 
Some biopsies are represented in row 1 and row 2 because both types of IM 
were present. Type IIB IM appears only in row 3.
Worst atypia/neoplasia score
Mucin 0 1 2 3 4 5
I 197 31 < 5 > 13
IIA 266 50 < 10 > 14
IIB 128 37 < 17 > 11
Table 5/12 . As 5/7, but combining dysplasia groups.
Worst atypia/neoplasia score
Mucin 0 1 2 3 4 5
I 228 (224) < 5(10) > 13(12)
IIA 316(309) < 10(14) > 14(17)
IIB 165 (176) < 17(8) > 11(9)
Table 5/13. As 5/8, but combining the groups with no atypia or reactive 
atypia and the dysplasia groups. Expected values are given in brackets 
except where the expected numbers are <5.
Using the figures in table 5/13 %2 = 15.7, (d.f. = 2, P = 0.0005),
and this %2 value is less entirely due to the deficiency of type I IM than 
the excess of type IIB IM in the dysplasia group.
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Chapter 6: Discussion
Oesophageal cancer remains a substantial challenge. In the West 
Barrett's cancer is increasingly recognised and in recent years it has 
overtaken squamous cancer, but remains less common in the Far East where 
squamous cancer of the oesophagus remains a major killer. Screening for 
cancer precursors or early cancers is an attractive strategy for reducing 
the impact for neoplastic diseases, and screening programmes have been 
implemented for cancer of the cervix and cancer of the breast and there 
are ongoing programmes which seek to develop screening for colon, 
prostate, lung and other common cancers. In point of fact, there are 
rather stringent requirements to be met before the costs of a screening 
programme can be justified, and in the case of oesophageal cancer these 
criteria are nowhere near met.
At the very least, a screening programme must have available a test 
or tests which is sensitive and specific for the disease entity (e.g. 
cervical intraepithelial neoplasia, early breast cancer, etc) which are 
to be detected, these values must translate, taking into consideration 
the actual incidence of the disease in the population being screened, 
into positive and negative predictive values sufficiently robust to avoid 
unnecessary anxiety caused by false positives without missing cases 
(false negatives), and there must be effective and acceptable treatments 
available, appropriate to the known risks associated with the disease.
In the case of the oesophagus, there are difficulties. In the 
West, most oesophageal adenocarcinoma presents in the context of 
Barrett's oesophagus, but occurs in patients not previously known to have 
had Barrett's oesophagus, so in order to have a substantial impact on 
oesophageal adenocarcinoma, it would almost inevitably be necessary to 
screen for Barrett's oesophagus; but there is major controversy about the 
exact size of the risk which is actually associated with Barrett's 
oesophagus, the size of that risk may have been substantially exaggerated 
as a consequence of publication bias [93].
66
Nevertheless, the possibility of effective screening and 
intervention remains important. While a case for screening for Barrett's 
oesophagus would be hard to justify at the present time [96], the fact 
remains that in the course of investigation for upper GI symptoms, many 
patients are identified with Barrett's oesophagus, and the question then 
arises what should be done about them in terms of follow up. Most of 
these people will never develop oesophageal adenocarcinoma, but some of 
them will, can those at risk be identified? This remains the key 
question, and the studies described in this thesis all had this question 
in the background.
Differentiating primary gastric cancer from oesophageal cancer can 
be difficult, especially when tumours involve both the stomach and 
oesophagus. Adenocarcinomas of both the stomach and oesophagus typically 
arise in a background of intestinal metaplasia. Carcinomas from the 
gastric cardia differ from those of the rest of the stomach. They share 
common epidemiological characteristics with oesophageal adenocarcinoma. 
Goldblum et al (58) found reflux systems to be more frequent in patients 
with SSBO than in those with cardiac IM. Additionally, patients with SSBO 
had a high male: female ratio, which is similar to LSBO, whereas patients 
with cardiac IM were found to be mostly female and to have a lower 
frequency of GORD systems.
Although dysplastic risk in IM of the cardia remains unclear,
Sharma et al (59) prospectively followed patients with SSBO and IM of the 
cardia and found the risk of dysplasia to be significantly greater in 
SSBO than in IM of the cardia, indicating two potentially different 
clinical processes. Regular endoscopic surveillance is required in 
patients with LSBE and is frequently performed in SSBE, but the need for 
surveillance in IM of the cardia is unknown. IM in SSBO and below the Z 
line can be histologically indistinguishable by haematoxylin and eosin 
sections. Additionally, endoscopically, an irregular Z-Line can be a 
normal finding and determination of where the oesophagus and the cardia 
begin can be unreliable.
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Ormsby et al (62) first described a Barrett's Ck7/20 
immunophenotype as superficial Ck20 staining and strong Ck7 staining of 
both superficial and deep glands in 94% of oesophageal resection 
specimens and in 100% of LSBO biopsy specimen or gastric resection 
specimens in patients with histological evidence IM. They found the 
Barrett's Ck7/20 pattern was highly sensitive and specific compared to 
cases with gastric IM and therefore could reliably identify the location 
of IM in the oesophagus and stomach. They later described a Ck 7 
positive, Ck 20 negative immunophenotype in 90% of patients with 
Barrett's oesophageal adenocarcinoma and only in 21% of gastric 
adenocarcinoma cases, so concluded this pattern to be potentially useful 
in accurate tumour classification.
Jovanovic et al (63) confirmed the immunophenotype described by 
Ormsby in 94% of LSBO cases, a pattern which was not seen in any of their 
36 cases with IM of the stomach. In cases with IM of the cardia, 93% 
expressed the Ck7/20 immunophenotype seen in the gastric mucosa. On the 
other hand, studies by some other researchers have not been able to 
support Ormby's findings. Mohammed et al (95) found that although the 
Barretts Ck7/20 was observed in many cases of Barrett's oesophagus, the 
sensitivity and specificity were only moderate (65% and 56% respectively) 
and that the cardiac IM pattern was variable. Additionally, where Ormsby 
(57) had described the Barrett's Ck7/20 pattern in 82% of patients with 
SSBE, not seen in any of their patients with gastric IM, Kurtkaya- 
Yapicier et al (96) found only 10% of patients with SSBE showed the 
anticipated Ck7/2 0 pattern. They found the two patterns of Ck7/20 to have 
low sensitivity and high false negativity values.
For this study the main purpose of this part of the work was to 
determine whether different IM phenotypes, in particular types IIA and 
IIB, might be associated with distinctive cytokeratin phenotypes which, 
in view of the association (described in chapter 5) between dysplasia 
risk and mucin phenotype might have been of some practical value. It does 
not appear that the prospects here are very encouraging. We find no
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difference in the Ck 7/ Ck 20 phenotypes for types IIA and IIB intestinal 
metaplasia and the numbers of type I cases are too small to be 
definitive. Ormsby et al [58,62,63] describe differences between 
oesophageal and gastric intestinal metaplasia patterns of Ck 7/ Ck 20 
expression which have generated a certain amount of interest as appearing 
to offer the prospect of being able to discriminate between short and 
ultra-short Barrett's oesophagus and gastric metaplasia at the gastric 
cardia, which appear to differ in the associated risk of neoplastic 
disease. Although this work did not address the question of gastric Ck 
7/Ck 20 patterns in many cases, the description of the phenotype 
recognised as characteristic by Ormsby et al (Gastric incomplete 
intestinal metaplasia: Ck7 weak superficial and deep, Ck20 patchy 
superficial and deep) clearly overlap with the patterns we are observing 
in classical Barrett's intestinal mucosa, and are unlikely therefore to 
be of great discriminatory power in that context.
Whether the reasons for the differences experienced in looking at 
the usefulness of Ck7/20 patterns in the oesophagus and stomach are due 
to inaccurate visualisation of SSBO or interobserver variability or 
possibly differences in tissue processing and staining techniques, it 
remains that if the results between groups are not comparable, Ck7/20 
immunophenotype cannot be reliably used to differentiate between IM taken 
from above or below the Z line.
This study supports the observation that Barrett's mucosa is 
phenotypically complex. It confirms the findings of other groups which 
describe a mixture of cardiac, fundic and specialised Barrett's in the 
lower oesophageal sphincter region and a mixture of cardiac, specialised, 
but rarely fundic mucosal types above this region, with several different 
mucosal phenotypes visible at a single level. As Barrett's epithelium may 
show as islands of columnar epithelium remote from the cardia [25] it is 
unlikely to evolve from a process of creeping substitution from the 
cardia but may develop ■fro.-'n cells intrinsic to the region. It has been 
postulated that stem cells in the oesophagus possess multipotentiality
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for cell differentiation and this could account for the variety of cell 
types seen in Barrett's epithelium. It could be that the luminal reflux 
contents may influence the morphology of the epithelium.
Specialised intestinal- type Barrett's mucosa is invariably present 
in LSBO and the previously reported association of dysplasia with 
intestinal Barrett's mucosa is very striking in our series [5,17,74].
The absence of obvious zonation of dysplasia in this study supports 
the previous observation, from relatively small patient numbers, that 
dysplasia is evenly distributed along the length of Barrett's oesophagus. 
McArdle et al [75] histologically evaluated the entire mucosal surface of 
7 oesophagectomy specimens with high grade dysplasia or early carcinoma. 
They showed an equal likelihood of high grade dysplasia or early invasive 
carcinoma occurring throughout the length of Barrett's epithelium with 
the amount of dysplastic epithelium related to the surface area of 
Barrett's epithelium but without an association between the extent of 
dysplasia and the likelihood of carcinoma. As mapping studies show 
dysplasia involving a variable amount of oesophageal mucosa [17, 75] the 
current recommendation for uniformly distributed endoscopic biopsies of 
the entire Barrett's segment is therefore supported.
The impressive association between dysplasia and intestinal 
metaplasia in our series confirms that endoscopic or molecular markers of 
intestinal phenotype might allow useful biopsy targeting [76], but only 
if a practical endoscopic technique of visualisation could be devised.
The data presented in chapter in chapter 4 confirm the presence of 
disrupted spacial organisation of cellular proliferation and maturation 
in both squamous oesophageal dysplasia and Barrett's dysplasia. 
Identifying these changes could be of practical significance in relation 
to the challenge of screening for squamous dysplasia in Oriental 
populations and Barrett's dysplasia in the West. The fact that both these 
conditions are characteristically associated with marked dysregulation of
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a family of proteins which are expressed at high levels suggests that 
these may have the potential to act as useful markers in their own right.
Patients with Barrett's oesophagus may be subjected to frequent 
endoscopy and biopsy. A sensitive and specific test for dysplasia might 
allow Barrett's patients to be screened for dysplasia and divided into a 
cohort without dysplasia, at a low risk of oesophageal adenocarcinoma, 
for whom less intensive follow up would be safe and a higher risk group 
with dysplasia, for whom more frequent endoscopic and biopsy surveillance 
could be appropriate.
Endoscopic surveillance is costly and unpleasant and biopsy 
sampling may miss focal areas of dysplasia. The superficial expression of 
Mcm2, Mem 5 anfd Ki 67 proteins by dysplastic Barrett's mucosa, suggests 
that exfoliative brush cytology could be used to increase sample areas. 
Non-endoscopic screening cytology has been attempted in Chinese 
populations [56] and the changes we have described suggest that this 
approach supplemented either by immunohistochemistry or biochemical 
determination of Mem proteins, could have a useful screening role.
Analogous to their application in a variety of other contexts such 
as screening the urinary tract for urothelial neoplasia, or screening 
smears for the lesionSwhich lead to invasive carcinoma of the cervix,
[91], this study supports the concept that Mem protein expression in 
dysplastic epithelia is associated with preneoplastic cells locked in the 
cell cycle (confirmed by persistance of positive Ki 67 expression).
In the stomach an incompletely differentiated variant of 
intestinal metaplasia secreting sulphomucins has been shown in several 
studies to be associated with the presence of gastric carcinoma of 
intestinal type. Jass [96] reported a similar association between this 
variant of IM and well differentiated adenocarcinoma arising in the 
columnar lined oesophagus and he suggested that the presence of this type 
of IM in oesophageal biopsies may serve as an important marker for
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identification of a sub group of patients at particular risk of 
developing oesophageal adenocarcinoma.
Haggitt et al [97] investigated the relationship of sulphated 
mucins, flow cytometry and histologic diagnosis in 152 biopsies from 42 
patients with histological diagnosis of dysplasia or carcinoma. They 
found sulphated mucins in non goblet columnar cells of Barrett's 
metaplastic epithelium (as detected by the high iron diamine-alcian blue 
stain) present in 73% of patient with histological diagnosis of dysplasia 
or carcinoma, 78% in patients whose biopsies were indefinite for 
dysplasia and in 55% of patients whose biopsies were negative for 
dysplasia . Abnormal flow cytometry was found in all patients with 
histological diagnosis of dysplasia or carcinoma, in 33% indefinite for 
dysplasia and in 5% negative for dysplasia. They concluded that the 
presence of sulphated mucin did not have sufficiently high sensitivity or 
specificity for dysplasia or carcinoma to be of value in managing 
patients whereas abnormal flow cytometry correlated extremely well with 
histological diagnosis of dysplasia and carcinoma and detected a subset 
of patients who were histologically indefinite or negative for 
dysplasia but who had flow cytometric abnormalities similar to those 
otherwise seen only in dysplasia and carcinoma.
The purpose of this part of the study was to see whether the presence 
of type IIB intestinal metaplasia, characterised by sulphomucins in 
columnar epithelium (non-goblet cells) might be strongly enough 
associated with dysplasia to be a useful biomarker to be exploited in 
biopsy screening for dysplasia in Barrett's oesophagus. There is indeed a 
positive association of type IIB intestinal metaplasia with dysplasia 
both at gastric and intestinal loci, but there is an even stronger 
association between type I intestinal metaplasia and the absence of 
dysplasia. Type I (complete) intestinal metaplasia implies a definite 
small intestinal phenotype and it is striking that this phenotype is 
negatively associated with dysplasia, given the rarity of dysplasia and 
primary adenocarcinoma in the small intestine. If incomplete types of
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intestinal metaplasia (types IIA and particularly IIB) are manifestations 
of a colonic mucosal phenotype, this may suggest a link with the much 
greater risk of neoplasia which exists in large bowel mucosa. Markers of 
differentiation in different parts of the bowel are increasingly well 
characterised [98,99] and such markers may allow easier phenotyping and 
ultimately risk stratification of the metaplastic mucosa in Barrett's.
The less than perfect kappa values associated with allocation of 
intestinal metaplasia to types I, IIA and IIB suggest that these 
characteristics themselves may not be sufficiently robust for routine 
clinical use. Such relatively modest agreement is very common in studies 
of pathological classification and diagnosis [100,101] and presumably 
reflects the subjective nature of these evaluations.
Conclusions.
It does not appear likely that Ck7/Ck20 phenotypes will be very 
useful in identifying an 'at risk' type of oesophageal intestinal 
metaplasia, as the expression patterns seem too variable to be highly 
distinctive. Nor is the size of the difference in the probability of 
dysplasia being associated with type IIA vs. type IIB intestinal 
metaplasia in Barrett's oesophagus likely to form the basis of a useful 
risk stratification. The decreased probability of dysplasia being found 
in the presence of Type I intestinal metaplasia seems more striking and 
interesting, and understanding the molecular underpinnings of these 
patterns of differentiation may give useful further information. It has 
sometimes been suggested that patients without evidence of intestinal 
metaplasia in Barrett's oesophagus are not at increased risk of cancer 
and need not be subjected to any ongoing surveillance, but an important 
finding is that such intestinal metaplasia is almost invariably present 
in Barrett's oesophagus if the density of biopsy taking is sufficient to 
detect it. It is not likely that many people will escape from 
surveillance in this manner. A much more plausible scenario is that 
patients in whom thorough biopsy has detected no evidence of dysplasia at
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any site are likely not to require further surveillance for at least 
several years and some centres are adopting a policy of less intensive 
surveillance in such patients. A corollary of this approach, of course, 
is that the detection of dysplasia by the reporting pathologist must be 
very precise, and we know that there are problems in this area. In this 
situation the rather robust upregulation of the Mem proteins in the 
dysplastic Barrett's mucosa is of interest and deserves evaluation as a 
potential marker of patients in whom expansion of neoplastic clones and 
subsequent cancer risk are greatest. This will ultimately require a 
relatively large scale prospective evaluation in order to be tested 
fully.
Finally, the distribution of the Mem proteins to the mucosal surface 
in dysplastic Barrett's mucosa offers the hope that non-endoscopic 
methods may eventually be able to sample the mucosal surface widely and 
that detection of aberrant Mem protein expression could identify patients 
requiring more intensive investigation by endoscopy and biopsy.
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